Back to Search
Start Over
The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets
- Source :
- Bioscience Reports, Vol 34, Iss 6, p e00147 (2014), Bioscience Reports
- Publication Year :
- 2014
- Publisher :
- Portland Press Ltd., 2014.
-
Abstract
- STS (soft tissue sarcomas) are rare malignant tumours deriving from cells of mesenchymal origin and represent only 1% of all malignant neoplasms. It has been extensively demonstrated that angiogenesis has an important role in cancer malignancy. Particularly, a lot of studies demonstrate the importance of angiogenesis in the development of carcinomas, whereas little is known about the role of angiogenesis in sarcomas and especially in STS. This review aims at summarizing the new discoveries about the nature and the importance of angiogenesis in STS and the new possible therapeutic strategies involved. Only a few studies concerning STS focus on tumour neovascularization and proangiogenic factors and look for a correlation with the patients prognosis/survival. These studies demonstrate that intratumoural MVD (microvessels density) may not accurately represent the angiogenic capacity of STS. Nevertheless, this does not exclude the possibility that angiogenesis could be important in STS. The importance of neoangiogenesis in soft tissue tumours is confirmed by the arising number of publications comparing angiogenesis mediators with clinical features of patients with STS. The efficacy of anti-angiogenic therapies in other types of cancer is well documented. The understanding of the involvement of the angiogenic process in STS, together with the necessity to improve the therapy for this often mortal condition, prompted the exploration of anti-tumour compounds targeting this pathway. In conclusion, this review emphasizes the importance to better understand the mechanisms of angiogenesis in STS in order to subsequently design-specific target therapies for this group of poorly responding tumours.<br />Angiogenesis is important for tumour growth and metastatization. The better understanding of the mechanisms of angiogenesis in soft tissue sarcomas can lead the design of specific target therapies for this group of poorly responding tumours.
- Subjects :
- Vascular Endothelial Growth Factor A
angiogenesis factors
Angiogenesis
lcsh:Life
lcsh:QR1-502
FGF-2, fibroblast growth factor-2
Angiogenesis Inhibitors
Review Article
Pregnancy Proteins
Matrix metalloproteinase
TKI, tyrosine kinase inhibitor
Biochemistry
lcsh:Microbiology
Neovascularization
angiogenesis
Neovascularization, Pathologic
Sarcoma
PlGF, placental growth factor
VEGF, vascular endothelial growth factor
MMP, matrix metalloproteinase
Vascular endothelial growth factor A
Fibroblast Growth Factor 2
medicine.symptom
S1
TIMP, tissue inhibitors of metalloproteinases
Biophysics
Antineoplastic Agents
mTOR, mammalian target of rapamycin
Biology
soft tissue sarcomas
Malignancy
Models, Biological
vWf, von-Willebrand factor
medicine
Humans
Molecular Biology
Placenta Growth Factor
STS, soft tissue sarcomas
VEGFR, VEGF receptor
EC, endothelial cell
target therapy
MVD, microvessels density
Mesenchymal stem cell
Cancer
Cell Biology
medicine.disease
Matrix Metalloproteinases
PDGFRβ, platelet-derived growth factor beta
uPa, urokinase-type plasminogen activator
MFH, malignant fibrous histiocytoma
lcsh:QH501-531
CSF, colony-stimulating factor
Immunology
Cancer research
Subjects
Details
- ISSN :
- 15734935 and 01448463
- Volume :
- 34
- Database :
- OpenAIRE
- Journal :
- Bioscience Reports
- Accession number :
- edsair.doi.dedup.....8ce7eda5bcfb7a98efbc409f79f7b540
- Full Text :
- https://doi.org/10.1042/bsr20140075